nach oben

Pathology & Oncology Research

Erschienen in:

21.12.2017 | Review

Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy

verfasst von: Qamar Ghafoor, Shobhit Baijal, Phillipe Taniere, Brendan O’Sullivan, Matthew Evans, Gary Middleton

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

A subset of patients with non-small cell lung cancer (NSCLC) respond well to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), due to the presence of sensitising mutations in the gene encoding EGFR. Mutations associated with resistance to first generation EGFR TKIs have also been identified, which lead to therapeutic failure and the requirement for new drugs. Three generations of EGFR TKIs have been developed and either have been, or are being, evaluated as first and/or second line therapeutic agents. In this review, we consider the advances in molecular diagnostic techniques that are used, or are in development, to facilitate the targeted EGFR TKI therapy of patients with NSCLC. A literature search was conducted in May 2017 using PubMed, and spanning the period September 2005 (EU approval date of erlotinib) to May 2017. Search terms used were: EGFR TKI, NSCLC, clinical trial, erlotinib, gefitinib, afatinib, EGFR mutations, Exon 19 deletion, and Leu858Arg. The use of molecular data, in conjunction with other clinical and diagnostic information, will assist physicians to make the best therapeutic choice for each patient with advanced NSCLC. Personalized medicine and a rapidly developing therapy landscape will enable these patients to achieve optimal responses to EGFR TKIs.

Dearden S, Stevens J, Wu YL, Blowers D (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol: official journal of the European Society for Medical Oncology / ESMO 24(9):2371–2376. https://doi.org/10.1093/annonc/mdt205 CrossRef

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol: official journal of the American Society of Clinical Oncology 23(4):857–865. https://doi.org/10.1200/JCO.2005.08.043 CrossRef

Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, Lee KD (2015) Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer 113(10):1519–1528. https://doi.org/10.1038/bjc.2015.356 CrossRefPubMedPubMedCentral

Cancer Genome Atlas Research N (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519–525. https://doi.org/10.1038/nature11404 CrossRef

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M, Spanish Lung Cancer G (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967. https://doi.org/10.1056/NEJMoa0904554 CrossRefPubMed

Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5(9):2892–2911PubMedPubMedCentral

European Medicines Agency (2005 (2014 version accessed)) Summary of Product Characteristics - Tarceva (erlotinib). http://www.ema.europa.eu/

European Medicines Agency (2009 (2014 version accessed)) Summary of Product Characteristics - Iressa (gefitinib). http://www.ema.europa.eu/

European Medicines Agency (2014) Summary of Product Characteristics - Giotrif (afatinib). http://www.ema.europa.eu/

10.

Juan O, Yousaf N, Popat S (2017) First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….. Clin Oncol (R Coll Radiol) 29(1):e1–e4. https://doi.org/10.1016/j.clon.2016.09.007 CrossRef

11.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. https://doi.org/10.1056/NEJMoa0810699 CrossRefPubMed

12.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742. https://doi.org/10.1016/S1470-2045(11)70184-X CrossRefPubMed

13.

Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV (2013) Symptom control and quality of life in LUX-lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol 31(27):3342–3350. https://doi.org/10.1200/JCO.2012.46.1764 CrossRef

14.

Passaro A, Gori B, de Marinis F (2013) Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-lung 3 and LUX-lung 6 phase III trials. J Thorac Dis 5(4):383–384. https://doi.org/10.3978/j.issn.2072-1439.2013.07.32 PubMedPubMedCentralCrossRef

15.

Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol 31(27):3327–3334. https://doi.org/10.1200/JCO.2012.44.2806 CrossRef

16.

Yang J-H, Sequist LV, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Geater SL, Zhou C, Massey D, Zazulina V, Wu Y-L, investigators on behalf oL-LaL-L Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) Epidermal Growth Factor Receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).. In: 50th American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Il, USA, 30 May–3 June 2014. p Abstract 21366

17.

Geater SL, Xu CR, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Palmer M, Shi Y, Lungershausen J, Wu YL (2015) Symptom and quality of life improvement in LUX-lung 6: an open-label phase III study of Afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non-small-cell lung cancer. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer 10(6):883–889. https://doi.org/10.1097/JTO.0000000000000517 CrossRef

18.

Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kolbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5):577–589. https://doi.org/10.1016/S1470-2045(16)30033-X CrossRefPubMed

19.

Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kolbeck K, Fan J, Dodd N, Marten A, Park K (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-lung 7 trial. Ann Oncol: official journal of the European Society for Medical Oncology / ESMO 28(2):270–277. https://doi.org/10.1093/annonc/mdw611 CrossRef

20.

Zugazagoitia J, Diaz A, Jimenez E, Nunez JA, Iglesias L, Ponce-Aix S, Paz-Ares L (2017) Second-line treatment of non-small cell lung cancer: focus on the clinical development of Dacomitinib. Front Med (Lausanne) 4:36. https://doi.org/10.3389/fmed.2017.00036 CrossRef

21.

Ramalingam SS, O'Byrne K, Boyer M, Mok T, Janne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L (2016) Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol: official journal of the European Society for Medical Oncology / ESMO 27(3):423–429. https://doi.org/10.1093/annonc/mdv593 CrossRef

22.

Ou SH, Soo RA (2015) Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Drug Des Devel Ther 9:5641–5653. https://doi.org/10.2147/DDDT.S52787 CrossRefPubMedPubMedCentral

23.

Mok T, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S, Tsuji R, Rosell R, Jaime J, Migliorino MR, Pluzanski A, Linke R, Sbar E, Wang T, Wu Y-L Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. In: American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA, 2–6 June 2017 2017

24.

Juan O, Popat S (2017) Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol 9(3):201–216. https://doi.org/10.1177/1758834016687262 CrossRefPubMedPubMedCentral

25.

Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, Reck M, Berghmans T, Wasag B, Besse B, Dziadziuszko R (2017) The APPLE trial: feasibility and activity of AZD9291 (Osimertinib) treatment on positive PLasma T790M in EGFR-mutant NSCLC patients. EORTC 1613. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2017.02.005

26.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Janne PA (2017) Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol Off J Am Soc Clin Oncol 35(12):1288–1296. https://doi.org/10.1200/JCO.2016.70.3223 CrossRef

27.

European Medicines Agency (2017) Tagrisso (osimertinib) Summary of Product Characteristics.. First published 02/2016. Updated 03/2017 edn.,

28.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, Investigators A (2017) Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629–640. https://doi.org/10.1056/NEJMoa1612674 CrossRefPubMed

29.

Yang J (2016) Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated phase 1 (P1) and pooled phase 2 (P2) results.. Paper presented at the European lung cancer conference (ELCC) 2016, Geneva. Switzerland, 14 April 2016

30.

Ramalingam S (2016) Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts.. Paper presented at the European lung cancer conference (ELCC) 2016, Geneva. Switzerland, 14 April 2016

31.

Ferguson KM (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37:353–373. https://doi.org/10.1146/annurev.biophys.37.032807.125829 CrossRefPubMedPubMedCentral

32.

Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181. https://doi.org/10.1038/nrc2088 CrossRefPubMed

33.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21(6):560–562. https://doi.org/10.1038/nm.3854 CrossRefPubMedPubMedCentral

34.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139. https://doi.org/10.1056/NEJMoa040938 CrossRefPubMed

35.

Evans M, O’Sullivan B, Hughes F, Swift C, Mullis T, Dessi R et al (2016) The sectrum of rare and complicated EGFR mutations in NSCLC: a series of 17, 047 tumours. NCRI Cancer Conferecne, Liverpool

36.

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–2247. https://doi.org/10.1158/1078-0432.CCR-12-2246 CrossRefPubMedPubMedCentral

37.

Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB (2013) Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 5(216):216ra177. https://doi.org/10.1126/scitranslmed.3007205 CrossRefPubMedPubMedCentral

38.

Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J (2005) Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 70:419–426. https://doi.org/10.1101/sqb.2005.70.043 CrossRefPubMed

39.

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W (2012) Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 39(2):366–372. https://doi.org/10.1183/09031936.00010111 CrossRefPubMed

40.

Wang J, Wang B, Chu H, Yao Y (2016) Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets Ther 9:3711–3726. https://doi.org/10.2147/OTT.S106399 CrossRef

41.

Kim EK, Kim KA, Lee CY, Shim HS (2017) The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS One 12(2):e0171280. https://doi.org/10.1371/journal.pone.0171280 CrossRefPubMedPubMedCentral

42.

Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G (2015) MET gene amplification and MET receptor activation are not sufficient to predict efficacy of combined MET and EGFR inhibitors in EGFR TKI-resistant NSCLC cells. PLoS One 10(11):e0143333. https://doi.org/10.1371/journal.pone.0143333 CrossRefPubMedPubMedCentral

43.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH (2016) Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer 11(9):1493–1502. https://doi.org/10.1016/j.jtho.2016.06.004 CrossRef

44.

Vendrell JA, Mau-Them FT, Beganton B, Godreuil S, Coopman P, Solassol J (2017) Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. Int J Mol Sci 18(2). https://doi.org/10.3390/ijms18020264

45.

Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M (2017) Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget 8(7):12501–12516. https://doi.org/10.18632/oncotarget.13915 CrossRefPubMed

46.

Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R (2013) EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66(2):79–89. https://doi.org/10.1136/jclinpath-2012-201194 CrossRefPubMed

47.

Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL (2013) Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol Off J Am Soc Clin Oncol 31(1):17–22. https://doi.org/10.1200/JCO.2012.43.1718 CrossRef

48.

Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90(3):509–515. https://doi.org/10.1016/j.lungcan.2015.10.004 CrossRefPubMed

49.

Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS (2014) Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia study (IPASS). Lung Cancer 83(2):174–181. https://doi.org/10.1016/j.lungcan.2013.11.021 CrossRefPubMed

50.

Chuang JC, Salahudeen AA, Wakelee HA (2016) Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. Expert Opin Pharmacother 17(7):989–993. https://doi.org/10.1517/14656566.2016.1162786 CrossRefPubMed

51.

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G, Biomarkers France c (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet 387(10026):1415–1426. https://doi.org/10.1016/S0140-6736(16)00004-0 CrossRefPubMed

52.

Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12(3 Pt 1):839–844. https://doi.org/10.1158/1078-0432.CCR-05-1846 CrossRefPubMed

53.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Francais de P-C, Associazione Italiana Oncologia T (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. https://doi.org/10.1016/S1470-2045(11)70393-X CrossRefPubMed

54.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol 26(15):2442–2449. https://doi.org/10.1200/JCO.2007.14.8494 CrossRef

55.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology G (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. https://doi.org/10.1016/S1470-2045(09)70364-X CrossRefPubMed

56.

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol: official journal of the American Society of Clinical Oncology 29(21):2866–2874. https://doi.org/10.1200/JCO.2010.33.4235 CrossRef

57.

Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151. https://doi.org/10.1016/S1470-2045(14)71173-8 CrossRefPubMed

58.

Astrazeneca (2017) Tagrisso significantly improves progression-free survival in the Phase III FLAURA trial for lung cancer. https://www.astrazeneca.com/media-centre/press-releases/2017/tagrisso-significantly-improves-progression-free-survival-in-the-phase-iii-flaura-trial-for-lung-cancer-27072017.html. Accessed 27 July 2017

59.

Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6. Lancet Oncol 16(7):830–838. https://doi.org/10.1016/S1470-2045(15)00026-1 CrossRefPubMed

60.

Popat S, Hughes L, O’Brien MER, Ahmad T, Lewanski C, Dernedde U, Jankowski P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Ngai Y, Hackshaw A (2016) Afatinib benefits patients with confirmed/suspected EGFR mutant NSCLC, unsuitable for chemotherapy (TIMELY phase II trial). Paper presented at the WCLC, Vienna, Austria, December 4-7 2016

61.

Park K, Tan E, Zhang L, Hirsh V, O’Byrne K, Boyer M, Yang J, Mok T, Peil B, Marten A, Paz-Ares L (2016) Afatinib versus gefitinib as first-line treatment for EGFR mutation-positive NSCLC patients aged ≥75 years: subgroup analysis of lux-lung 7. Paper presented at the WCLC, Vienna, Austria, December 4-7 2016

Titel: Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy
verfasst von: Qamar Ghafoor
Shobhit Baijal
Phillipe Taniere
Brendan O’Sullivan
Matthew Evans
Gary Middleton
Publikationsdatum: 21.12.2017
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0377-1

Springer Medizin

Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Knockdown of Sox2 Inhibits OS Cells Invasion and Migration via Modulating Wnt/β-Catenin Signaling Pathway

The ER – Glycogen Particle – Phagophore Triangle: A Hub Connecting Glycogenolysis and Glycophagy?

TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours

Oral Health May Affect the Performance of mRNA-Based Saliva Biomarkers for Oral Squamous Cell Cancer

Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma?

Molecular Signature of Tumors with Monoallelic 13q14 Deletion: a Case Series of Spindle Cell Lipoma and Genetically-Related Tumors Demonstrating a Link Between FOXO1 Status and p38 MAPK Pathway

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie